Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2007 1
2009 3
2010 4
2011 2
2012 4
2013 2
2014 1
2015 4
2016 6
2017 10
2018 13
2019 9
2020 14
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Results by year
Filters applied: . Clear all
Page 1
Ovarian Cancer: A Heterogeneous Disease.
Kossaï M, Leary A, Scoazec JY, Genestie C. Kossaï M, et al. Among authors: genestie c. Pathobiology. 2018;85(1-2):41-49. doi: 10.1159/000479006. Epub 2017 Oct 12. Pathobiology. 2018. PMID: 29020678 Free article.
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I. Rousset-Jablonski C, et al. Among authors: genestie c. Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. Bull Cancer. 2018. PMID: 29397916 French.
Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP.
Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, Ray-Coquard I. Gladieff L, et al. Among authors: genestie c. Bull Cancer. 2017 May;104 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(17)30158-3. Bull Cancer. 2017. PMID: 28625311 French.
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A. Auguste A, et al. Among authors: genestie c. Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28. Mod Pathol. 2018. PMID: 29955143 Free article.
Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.
Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, Oosting J, Singh N, Smit HCSH, Smit VTHBM, Van de Vijver KK, Bosse T. Peters EEM, et al. Among authors: genestie c. Histopathology. 2019 Jul;75(1):128-136. doi: 10.1111/his.13871. Epub 2019 Jun 10. Histopathology. 2019. PMID: 31155736 Free PMC article. Clinical Trial.
[SCCOHT/ovarian rhabdoid tumor: A case report].
Bourgoin R, Cornelis F, Masliah-Planchon J, Genestie C, Laé M. Bourgoin R, et al. Among authors: genestie c. Ann Pathol. 2019 Sep;39(5):357-363. doi: 10.1016/j.annpat.2019.02.005. Epub 2019 Mar 27. Ann Pathol. 2019. PMID: 30928254 Review. French.
Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, Guillou L, Stoeckle E, Devouassoux-Shisheboran M, Penel N, Floquet A, Arnould L, Guyon F, Mishellany F, Chakiba C, Cuppens T, Zikan M, Leroux A, Frouin E, Farre I, Genestie C, Valo I, MacGrogan G, Chibon F. Croce S, et al. Among authors: genestie c. Mod Pathol. 2018 May;31(5):816-828. doi: 10.1038/modpathol.2017.185. Epub 2018 Jan 12. Mod Pathol. 2018. PMID: 29327710 Free article.
Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
Genestie C, Blanc-Durand F, Auguste A, Pautier P, Dunant A, Scoazec JY, Gouy S, Morice P, Bentivegna E, Maulard A, LeFormal A, Devouassoux-Shisheboran M, Leary A. Genestie C, et al. Br J Cancer. 2020 Feb;122(4):564-568. doi: 10.1038/s41416-019-0687-z. Epub 2019 Dec 17. Br J Cancer. 2020. PMID: 31844183
Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.
Cluzet V, Devillers MM, Petit F, Chauvin S, François CM, Giton F, Genestie C, di Clemente N, Cohen-Tannoudji J, Guigon CJ. Cluzet V, et al. Among authors: genestie c. Oncogene. 2020 Feb;39(9):1875-1890. doi: 10.1038/s41388-019-1109-7. Epub 2019 Nov 19. Oncogene. 2020. PMID: 31745296
66 results
Jump to page
Feedback